0.69 is Aveo Pharmaceuticals Inc’s (NASDAQ:AVEO) Institutional Investor Sentiment

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Logo

Sentiment for Aveo Pharmaceuticals Inc (NASDAQ:AVEO)

Aveo Pharmaceuticals Inc (NASDAQ:AVEO) institutional sentiment decreased to 0.69 in 2019 Q1. Its down -0.60, from 1.29 in 2018Q4. The ratio dived, as 29 active investment managers increased and started new holdings, while 42 sold and reduced stock positions in Aveo Pharmaceuticals Inc. The active investment managers in our partner’s database now own: 45.06 million shares, down from 48.91 million shares in 2018Q4. Also, the number of active investment managers holding Aveo Pharmaceuticals Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 21 Reduced: 21 Increased: 18 New Position: 11.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $105.90 million. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

The stock increased 1.32% or $0.0086 during the last trading session, reaching $0.6588. About 611,567 shares traded. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has declined 70.30% since August 13, 2018 and is downtrending. It has underperformed by 70.30% the S&P500.

Nea Management Company Llc holds 0.89% of its portfolio in AVEO Pharmaceuticals, Inc. for 20.90 million shares. New Leaf Venture Partners L.L.C. owns 402,118 shares or 0.09% of their US portfolio. Moreover, Gsa Capital Partners Llp has 0.06% invested in the company for 688,431 shares. The Massachusetts-based Excalibur Management Corp has invested 0.04% in the stock. Wealthtrust Axiom Llc, a Pennsylvania-based fund reported 138,505 shares.

Since January 1, 0001, it had 9 insider buys, and 0 insider sales for $44.61 million activity.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage

Ratings analysis reveals 50% of AVEO Pharma’s analysts are positive. Out of 2 Wall Street analysts rating AVEO Pharma, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $1 while the high is $3. The stock’s average target of $2 is 203.58% above today’s ($0.6588) share price. AVEO was included in 5 notes of analysts from February 19, 2019. Piper Jaffray maintained the shares of AVEO in report on Tuesday, February 19 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Hold” on Monday, March 18.

More notable recent AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news were published by: Nasdaq.com which released: “AVEO (AVEO) Upgraded to Buy: What Does It Mean for the Stock? – Nasdaq” on March 19, 2019, also Nasdaq.com with their article: “Why AVEO Oncology Stock Is Crashing Today – Nasdaq” published on January 31, 2019, Seekingalpha.com published: “AVEO Pharmaceuticals Gets Sideswiped – Seeking Alpha” on February 05, 2019. More interesting news about AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) were released by: Nasdaq.com and their article: “U.S. STOCKS ON THE MOVE-Fitbit, Whiting Petroleum, IZEA Worldwide, AVEO Pharmaceuticals – Nasdaq” published on August 01, 2019 as well as Seekingalpha.com‘s news article titled: “AVEO Acquisition Rumors Resuscitate The Stock – Seeking Alpha” with publication date: April 02, 2019.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.